Document is current
Any future updates will be listed below
-
Authors
Tvorogov, Denis https://orcid.org/0000-0002-2009-1347
Thompson‐Peach, Chloe A L https://orcid.org/0000-0001-7172-3183
Foßelteder, Johannes https://orcid.org/0000-0002-0241-6822
Dottore, Mara https://orcid.org/0000-0002-0254-6598
Stomski, Frank
Onnesha, Suraiya A
Lim, Kelly https://orcid.org/0000-0003-4606-7588
Moretti, Paul A B https://orcid.org/0000-0002-3523-1496
Pitson, Stuart M https://orcid.org/0000-0002-9527-2740
Ross, David M
Reinisch, Andreas https://orcid.org/0000-0001-9333-7689
Thomas, Daniel https://orcid.org/0000-0002-0837-1231
Lopez, Angel F https://orcid.org/0000-0001-7430-0135
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1182564)
Department of Health | National Health and Medical Research Council (APP 2004288)
Commonwealth Serum Laboratories (2020_CSL_Thomas)
Hospital Research Foundation (C‐PJ‐173‐Exper‐2019)
Australian Medical Research Future Fund (2008972)
Austrian Science Fund (P32783)
Austrian Science Fund (I5021)
Leukemia & Lymphoma Society (LLS 6619‐21)
Austrian Society of Internal Medicine (Joseph‐Skoda Award)
Austrian Society of Haematology and Medical Oncology (Clinical Research Grant)
MEFOgraz
Council of Australian University Librarians
- License Information
-
More Information
Article History
Received: 10 June 2021
Revised: 23 January 2022
Accepted: 26 January 2022
First Online: 14 February 2022
Disclosure and competing interests statement
: DT, DTv and AR are recipients of Australian Medical Research Future Fund for Rare Diseases, Rare Cancers and Unmet Need. DR receives research support from Novartis and Bristol Myers Squib, Honoraria and consultancy from Novartis, Bristol Myers Squib and Keros Therapeutics. AR receives research support from Celgene and is a consultant for Pfizer. None of these agencies have had a role in the preparation of this manuscript. The remaining authors declare no competing interests.
